{"title":"GitHub and Google Colab for Sharing Data and Code.","authors":"David Wesley","doi":"10.17849/insm-53-2-1-4.1A","DOIUrl":"10.17849/insm-53-2-1-4.1A","url":null,"abstract":"<p><p>A traditional print journal is not ideal for the dissemination of computer code and related data. Without the actual code and data, reproducibility cannot be assessed, and there can be no validation of the premise of such an article. Fortunately, there are inexpensive modern ways to share both data and code while providing for explanatory text: GitHub and Google Colaboratory. This article introduces both and provides 3 different examples for the reader to experience.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"199-202"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When Is a Test \"Genetic?\" The Case of Multi-Cancer Early Detection Tests.","authors":"Timothy Meagher","doi":"10.17849/insm-53-2-1-4.1B","DOIUrl":"10.17849/insm-53-2-1-4.1B","url":null,"abstract":"<p><p>Multi-cancer early detection (MCED) tests are increasingly popular. Are these tests \"genetic,\" and if so, can insurers use them in the risk assessment process? This article reviews definitions of genetic tests. It then reviews the motivation for limiting insurers' access to genetic tests and examines the wording in the legislation in 3 English speaking jurisdictions. It then attempts to establish whether MECD results are included in the legislation.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"217-220"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Coronary Artery Calcium Score - Practical Considerations for Underwriting.","authors":"Emoke Posan","doi":"10.17849/insm-53-2-1-7.1A","DOIUrl":"10.17849/insm-53-2-1-7.1A","url":null,"abstract":"<p><p>This brief practical review explores the fundamentals of coronary artery calcium score testing, its role in cardiovascular risk stratification, and how it can empower underwriting CV risks with greater clarity, speed, and confidence.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"192-198"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Creating Evidence-Based Ratings and Life Expectancies Medical Impairments.","authors":"John R Iacovino","doi":"10.17849/insm-53-2-1-4.1","DOIUrl":"10.17849/insm-53-2-1-4.1","url":null,"abstract":"<p><p>Accurate and profitable risk selection requires evidence-based survival information. Medical Impairment Manual (MIM) ratings and life expectancies can be determined from illustrated survival and/or mortality curves in the medical literature. This article illustrates how to utilize these curves to calculate MIM ratings and life expectancy estimations.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"124-127"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natalia Reyes-Cancino, Elyssa Del Valle, Asha Sapre, José Chedid
{"title":"The Smoking Dilemma: A Technical Deep Dive.","authors":"Natalia Reyes-Cancino, Elyssa Del Valle, Asha Sapre, José Chedid","doi":"10.17849/insm-53-2-1-13.1","DOIUrl":"10.17849/insm-53-2-1-13.1","url":null,"abstract":"<p><p>Traditional cigarette smoking has declined markedly over recent decades due to increased health awareness, regulatory action, and public health campaigns. At the same time, alternative nicotine products, particularly e-cigarettes and oral nicotine pouches, have gained popularity, especially in the United States and Europe and among younger populations. While cigarettes remain the most widely used tobacco product globally, tobacco and nicotine consumption now spans a broad range of combustible and non-combustible products, with smokeless tobacco predominating in some regions. Definitions of a \"smoker\" vary significantly between clinical practice and insurance medicine. Clinical definitions are nuanced and health-focused, whereas insurance classifications are typically binary and time-bound, often defining a smoker as anyone who has used a nicotine-containing product within the past 12 months. The growing use of alternative nicotine products, alongside evolving cannabis legislation, has exposed limitations in traditional definitions when it comes to accurately capturing associated risk. The expansion of alternative nicotine products challenges traditional smoker classifications used in insurance underwriting. While combustible tobacco remains the highest risk exposure, growing evidence supports the existence of a heterogeneous medium risk group associated with nicotine, noncombustible products. Although generally lower risk than cigarettes, these products are not risk-free, particularly considering early cardiovascular and metabolic effects, dual or poly-use patterns, and growing uptake at younger ages. For insurers, this evolving landscape highlights the benefit of a more nuanced underwriting approach, including enhanced disclosure of product type and use patterns, improved verification strategies, and potential pricing differentiation that better aligns risk with exposure.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"135-147"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Problems Using Body Mass Index (BMI) to Assess Mortality.","authors":"Rodney C Richie","doi":"10.17849/insm-53-2-1-5.1A","DOIUrl":"10.17849/insm-53-2-1-5.1A","url":null,"abstract":"<p><p>There is increasing unease in the medical community about using the predictive value of the body measurement index (BMI) as a guide to an individual's current and future health. Elevated BMIs are evaluated by life and disability underwriters as part of a comprehensive review, but other than verifying overweight status, the predictive value of BMI on future morbidity and mortality is questionable until the BMI is >35, and several studies have shown better mortality in the \"overweight\" BMI 25-29.9 category than in the \"normal\" BMI 18.5-24.9 category. The goal of this treatise is to evaluate other anthropomorphic measurements that might be better predictors of future health.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"187-191"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022.","authors":"Anthony F Milano","doi":"10.17849/insm-53-2-1-34.1","DOIUrl":"10.17849/insm-53-2-1-34.1","url":null,"abstract":"<p><p>Prostate cancer is a major cause of disease and mortality among older men (mean age 67.3 years old) in the United States and globally. Given the biological heterogeneity of this cancer in this short- and long-term United States retrospective population-based analysis, the focus is on incidence, mortality, and survival by age, race/ethnicity, stage, and severity in cohort entry time periods (1975-99 and 2000-22), and disease duration. This comparative cohort short- and long-term study is intended to provide age-adjusted epidemiologic and demographic survival and mortality data for convenient reference by all physicians, scientists, insurance underwriters, and others interested in cancer mortality follow-up.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"148-181"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hazard Ratio to Life Expectancy: Gompertz-Makeham Validation of Emerging Risk Factors Collaboration Cardiometabolic Multimorbidity Tables.","authors":"Bernard Silke","doi":"10.17849/insm-53-2-1-7.1B","DOIUrl":"10.17849/insm-53-2-1-7.1B","url":null,"abstract":"<p><strong>Objective.—: </strong>To validate Emerging Risk Factors Collaboration (ERFC) high-risk cardiometabolic life years lost (LYL) tables using Gompertz-Makeham calibrated to hazard ratios, offering a reproducible framework for insurance underwriting and medico-legal life expectancy projections.</p><p><strong>Methods.—: </strong>ERFC LYL tables (91 cohorts; 689,300 participants; HR≥5) benchmarked against Irish Life Tables No. 17 via constant HR∼9.5 multiplier. Gompertz-Makeham generated risk-group survival curves; LYL as baseline-risk differential ages 40-85. Model performance via mean absolute error (MAE).</p><p><strong>Results.—: </strong>Gompertz-Makeham reproduced ERFC high-risk LYL (males MAE 1.21 years; females 1.16 years across 40-85), preserving empirical S-curve without disease-specific adjustments (Table 2; Figures 1-3). Age 40 loses, 20-22 years; age 75, 5-6 years.</p><p><strong>Conclusions.—: </strong>HR-calibrated Gompertz-Makeham provides aetiology-independent LYL estimates within 1 - 2 years mean absolute error (MAE), extending Strauss/Shavelle disability models to multimorbidity for actuarial risk assessment and forensic reports.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"203-209"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antoine Moll, Denis Charles, Zeynep Kaya, Manuel Plisson, Julien Tomas, Irene Merk, Viet Chi Tran, Thierry Jeantheau, Pierre Sabouret
{"title":"Disability Risk for Male Professional Soccer Players: A Question of Age? A New Method Based on Transfermarkt®'s Collaborative Data.","authors":"Antoine Moll, Denis Charles, Zeynep Kaya, Manuel Plisson, Julien Tomas, Irene Merk, Viet Chi Tran, Thierry Jeantheau, Pierre Sabouret","doi":"10.17849/insm-53-2-1-7.1C","DOIUrl":"10.17849/insm-53-2-1-7.1C","url":null,"abstract":"<p><p>The soccer industry generates billions in revenue, largely from matchday sales, commercial activities, and television rights. A significant portion of club revenues are spent on player wages making their availability for games and training economically vital. Any period of injury-related absence functions as a form of temporary disability, creating significant financial exposure for teams, insurers, and reinsurers. Preventing injuries is crucial for soccer clubs to mitigate financial and sports risks associated with player unavailability. Transfermarkt® database has been utilized to develop an accurate method to estimate the incidence of injuries among male soccer players. To propose the most appropriate preventive measures, medical teams of soccer clubs should consider other risk factors than age, such as the history of injuries and the player's position in the field. This new model offers a practical framework for insurers, reinsurers, and club medical teams to better quantify disability risk, refine prevention strategies, and improve the prediction of injury-related downtime.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"210-216"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GLP-1 Therapies and Mortality Risk: Implications for Life Insurers.","authors":"Gina C Guzman, Tristan Walsh","doi":"10.17849/insm-53-2-1-7.1","DOIUrl":"10.17849/insm-53-2-1-7.1","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly expanded beyond their initial role in diabetes management, demonstrating therapeutic potential across a range of non-diabetic conditions. Due to their potential to improve mortality and morbidity outcomes, GLP-1 drugs are becoming an increasingly salient topic for insurers, particularly in relation to mortality improvement, medical underwriting, and new product development. Our large-scale mortality study estimates that GLP-1 drugs may drive 0.2%-0.5% annual mortality improvement, realized over a 20-year period. Low adherence could limit long-term mortality benefits, and electronic health records will be vital for accurately assessing metabolic risk in underwriting. The mortality benefits identified for GLP-1 drugs present opportunities for carriers to transform how they assess metabolic risk in underwriting programs. However, variation in individual risk profiles, driven by poor adherence and inconsistent behavioral change, as well as other factors, underscores the need for nuance in program design and application.</p>","PeriodicalId":39345,"journal":{"name":"Journal of insurance medicine (New York, N.Y.)","volume":"53 2","pages":"128-134"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148266477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}